Literature DB >> 11479141

Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.

G P Thomas1, S U Baker, J A Eisman, E M Gardiner.   

Abstract

Osteoblast-osteoclast coordination is critical in the maintenance of skeletal integrity. The modulation of osteoclastogenesis by immature cells of the osteoblastic lineage is mediated through receptor activator of NF kappa B (RANK), its ligand RANKL, and osteoprotegerin (OPG), a natural decoy receptor for RANKL. Here, the expression of OPG and RANKL in primary mouse osteoblastic cultures was investigated to determine whether the osteoclastogenic stimulus depended on the stage of osteoblastic differentiation and the presence of the calciotrophic hormone 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). OPG mRNA expression was increased in osteoblastic cultures after the onset of mineralisation relative to less mature cultures, but did not alter in response to 1,25-(OH)(2)D(3) treatment. In contrast, basal RANK L mRNA expression did not change during differentiation but was significantly enhanced by 1,25-(OH)(2)D(3) treatment at all times. The stimulatory effects of 1,25-(OH)(2)D(3) on RANKL were lessened in more mature cultures, however. The RANKL/OPG ratio, an index of osteoclastogenic stimulus, was therefore increased by 1,25-(OH)(2)D(3) treatment at all stages of osteoblastic differentiation, but to a lesser degree in cultures after the onset of mineralisation. Thus the 1,25-(OH)(2)D(3)-driven increase in osteoclastogenic potential of immature osteoblasts appears to be mediated by increased RANKL mRNA expression, with mature osteoblasts having relatively decreased osteoclastogenic activity due to increased OPG mRNA expression. These findings suggest a possible mechanism for the recently proposed negative regulatory role of mature osteoblasts on osteoclastogenesis and indicate that the relative proportions of immature and mature osteoblasts in the local microenvironment may control the degree of resorption at each specific bone site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479141     DOI: 10.1677/joe.0.1700451

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  45 in total

1.  TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women.

Authors:  Yan Lu; Pengyuan Liu; Robert R Recker; Hong-Wen Deng; Volodymyr Dvornyk
Journal:  Menopause       Date:  2010 Sep-Oct       Impact factor: 2.953

Review 2.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

3.  Production, characterisation, and cytocompatibility of porous titanium-based particulate scaffolds.

Authors:  B J C Luthringer; F Ali; H Akaichi; F Feyerabend; T Ebel; R Willumeit
Journal:  J Mater Sci Mater Med       Date:  2013-06-27       Impact factor: 3.896

4.  Peripheral cannabinoid receptor, CB2, regulates bone mass.

Authors:  Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; Raphael Mechoulam; Andreas Zimmer; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

5.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  Histopathological assessment of prostate cancer bone osteoblastic metastases.

Authors:  Martine P Roudier; Colm Morrissey; Lawrence D True; Celestia S Higano; Robert L Vessella; Susan M Ott
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

7.  The cytoskeletal regulatory scaffold protein GIT2 modulates mesenchymal stem cell differentiation and osteoblastogenesis.

Authors:  Xiaojuan Wang; Shaoxi Liao; Erik R Nelson; Robert Schmalzigaug; Robert F Spurney; Farshid Guilak; Richard T Premont; Diane Gesty-Palmer
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

8.  Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.

Authors:  Jenna E Fong; Damien Le Nihouannen; Svetlana V Komarova
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

9.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Authors:  Suthinee Ithimakin; Kathleen C Day; Fayaz Malik; Qin Zen; Scott J Dawsey; Tom F Bersano-Begey; Ahmed A Quraishi; Kathleen Woods Ignatoski; Stephanie Daignault; April Davis; Christopher L Hall; Nallasivam Palanisamy; Amber N Heath; Nader Tawakkol; Tahra K Luther; Shawn G Clouthier; Whitney A Chadwick; Mark L Day; Celina G Kleer; Dafydd G Thomas; Daniel F Hayes; Hasan Korkaya; Max S Wicha
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701

10.  Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response.

Authors:  G J Atkins; K J Welldon; P Halbout; D M Findlay
Journal:  Osteoporos Int       Date:  2008-09-02       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.